The goal of this paper is to develop fast algorithms for signal reconstruction from magnitudes of frame coefficients. This
problem is important to several areas of research in signal processing, especially speech recognition technology, as well
as state tomography in quantum theory. We present linear reconstruction algorithms for tight frames associated with projective
2-designs in finite-dimensional real or complex Hilbert spaces. Examples of such frames are two-uniform frames and mutually
unbiased bases, which include discrete chirps. The number of operations required for reconstruction with these frames grows
at most as the cubic power of the dimension of the Hilbert space. Moreover, we present a very efficient algorithm which gives
reconstruction on the order of d operations for a d-dimensional Hilbert space. 相似文献
A cationic palladium complex catalyzes the title transformations, which are thought to proceed via a π‐allyl or π‐benzyl intermediate. The regioselectivity of the reaction (1,2‐ or 1,1‐difunctionalization) depends on the type of terminal double bond (conjugated or nonconjugated) in the substrate (see scheme) and appears to be controlled by the relative rates of β‐hydride elimination and transmetalation. DMA=dimethylacetamide, Tf=triflyl.
We consider the stochastic wave equation with multiplicative noise, which is fractional in time with index H > 1/2, and has a homogeneous spatial covariance structure given by the Riesz kernel of order α. The solution is interpreted using the Skorohod integral. We show that the sufficient condition for the existence of the
solution is α > d − 2, which coincides with the condition obtained in Dalang (Electr J Probab 4(6):29, 1999), when the noise is white in time. Under this condition, we obtain estimates for the p-th moments of the solution, we deduce its H?lder continuity, and we show that the solution is Malliavin differentiable of
any order. When d ≤ 2, we prove that the first-order Malliavin derivative of the solution satisfies a certain integral equation. 相似文献
Parkinson’s disease (PD) and Alzheimer’s disease (AD) are neurodegenerative disorders that have emerged as among the serious health problems of the 21st century. The medications currently available to treat AD and PD have limited efficacy and are associated with side effects. Natural products are one of the most vital and conservative sources of medicines for treating neurological problems. Karanjin is a furanoflavonoid, isolated mainly from Pongamia pinnata with several medicinal plants, and has been reported for numerous health benefits. However, the effect of karanjin on AD and PD has not yet been systematically investigated. To evaluate the neuroprotective effect of karanjin, extensive in silico studies starting with molecular docking against five putative targets for AD and four targets for PD were conducted. The findings were compared with three standard drugs using Auto Dock 4.1 and Molegro Virtual Docker software. Additionally, the physiochemical properties (Lipinski rule of five), drug-likeness and parameters including absorption, distribution, metabolism, elimination and toxicity (ADMET) profiles of karanjin were also studied. The molecular dynamics (MD) simulations were performed with two selective karanjin docking complexes to analyze the dynamic behaviors and binding free energy at 100 ns time scale. In addition, frontier molecular orbitals (FMOs) and density-functional theory (DFT) were also investigated from computational quantum mechanism perspectives using the Avogadro-ORCA 1.2.0 platform. Karanjin complies with all five of Lipinski’s drug-likeness rules with suitable ADMET profiles for therapeutic use. The docking scores (kcal/mol) showed comparatively higher potency against AD and PD associated targets than currently used standard drugs. Overall, the potential binding affinity from molecular docking, static thermodynamics feature from MD-simulation and other multiparametric drug-ability profiles suggest that karanjin could be considered as a suitable therapeutic lead for AD and PD treatment. Furthermore, the present results were strongly correlated with the earlier study on karanjin in an Alzheimer’s animal model. However, necessary in vivo studies, clinical trials, bioavailability, permeability and safe dose administration, etc. must be required to use karanjin as a potential drug against AD and PD treatment, where the in silico results are more helpful to accelerate the drug development. 相似文献